Xu, W., Shi, S., Wang, J., Xu, Y., Tian, X., Wan, F., . . . Ye, D. (2019). The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma. Med Sci Monit.
Style de citation ChicagoXu, Wen-Hao, et al. "The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) As a Clinicopathological and Prognostic Biomarker in Patients With Clear Cell Renal Cell Carcinoma." Med Sci Monit 2019.
Style de citation MLAXu, Wen-Hao, et al. "The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) As a Clinicopathological and Prognostic Biomarker in Patients With Clear Cell Renal Cell Carcinoma." Med Sci Monit 2019.
Attention : ces citations peuvent ne pas être correctes à 100%.